Strong Financials Drive Star Health's FY26 Performance

Star Health's robust financial results for the fiscal year ending March 31, 2026, showed operational improvements driven by premium growth and a better loss ratio. This positive news initially boosted the company's share price, supported by a generally higher Nifty 50.

Key Growth Drivers and Profitability Metrics

The company reported a Profit After Tax (PAT) of ₹911 crore for FY26, a 16% year-on-year increase. This was driven by a 16% growth in Gross Written Premium (GWP) to ₹20,369 crore. Retail health premiums were a standout, advancing 20% to ₹19,341 crore, reinforcing Star Health's 31% market share in this segment. The combined ratio improved significantly to 98.8% for the full fiscal year, down from 101.1% in FY25, signaling better loss ratios and operational efficiency. The fourth quarter (Q4 FY26) saw a combined ratio of 95.7%, an improvement from 98.4% a year earlier. These strong figures led to an initial jump in Star Health's stock price, which rose as much as 13.32% before easing.

Sector Context and Valuation Comparison

The overall Indian non-life insurance sector saw substantial growth in FY26, with gross premiums reaching about ₹3.36 lakh crore, up 9% year-on-year. Health insurance led the expansion, growing 15.6% to ₹1.37 lakh crore, largely driven by retail policies. Star Health's performance in its retail segment mirrors this broader industry trend. However, its valuation faces scrutiny. Star Health's trailing P/E ratio of approximately 38.4x as of April 2026 is higher than competitors like ICICI Lombard, whose TTM P/E ranges from 31.88x to 37.75x. SBI General Insurance, meanwhile, often shows a more conservative P/E profile as it pursues market share. Historically, investors have closely watched Star Health's ability to sustain margin improvements, sometimes leading to stock price moderation after initial gains from strong growth figures.

Valuation Concerns and Growth Target Revision

Despite strong results, Star Health's valuation metrics require close examination. Its P/E ratio of 38.4x is higher than many competitors. The company's Return on Equity (ROE) has been modest, reported between 6.70% and 9.67% recently, which may not fully support its current market valuation against industry peers. Additionally, Star Health has revised its FY28 Gross Written Premium target downwards to ₹27,500 crore from ₹30,000 crore. This indicates a potential shift from aggressive expansion towards a more profit-focused strategy, possibly reflecting market saturation or increased competition. Management highlights disciplined execution, but sustained improvement in loss ratios is crucial, particularly with intensifying competition and ongoing pricing adjustments. Investor confidence in margin sustainability has previously been fragile, sometimes causing stock price dips even after positive earnings reports.

Analyst Outlook and Corporate Governance

Analysts remain largely positive on Star Health, with a consensus 'Buy' rating from 22 analysts and an average 12-month price target of ₹528.14. Motilal Oswal Financial Services reiterated its 'Buy' rating, expecting continued growth from the retail health segment and its banca channel. Management is focused on sustainable growth, digital innovation, and expanding insurance access in India. Recent corporate updates include the approval of an amended Insider Trading Policy and promoter reclassification. The company's board also gave its approval for the audited FY26 results, which received an unmodified audit opinion.